UNSPSC 51433507: Mibefradil dihydrochloride

This classification denotes a calcium channel blocker with the molecular formula C29H38FN3O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 842TUP3PQ8, chemically known as acetic acid, methoxy-, 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride, (1s-cis)-, but more generally known as mibefradil dihydrochloride, which bears US NIH Compound Identifier 60662.

UNSPSC 51433507 Mibefradil dihydrochloride is a Commodity code covering individual pharmaceutical active ingredients and finished-form medications procured by state and local health agencies, fire rescue services, and pharmacy benefit programs. State and local governments buy under this code to stock emergency medical supplies, support pharmacy benefit programs, and fulfill direct-to-manufacturer procurement initiatives. Recent solicitations reflect demand for advanced life support medications, generic multi-source pharmaceuticals, and therapeutic pharmacy program implementations across city fire departments, state health commissions, and multistate cooperative purchasing alliances.

The City of Tampa's Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing-body mix, spanning municipal fire services, state health agencies, and cooperative purchasing vehicles serving multiple jurisdictions. Tampa Fire Rescue is soliciting sealed bids (IFB No. 26P00188) for four specific advanced life support medication line items—Labetalol HCI, Epinephrine, Adenosine, and Diltiazem—with an estimated contract value of $40,000 and response deadline of April 8, 2026. MMCAP has issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The Texas HHS Commission has posted an RFI (HHS0017013) seeking vendor capabilities for direct-to-manufacturer prescription programs to inform future formal procurement strategy. Activity concentrates in Texas, Minnesota, and Florida, with MMCAP's multistate reach extending procurement interest across the upper Midwest and Pacific Northwest.